CD274 and neoplasm: The combination of PEGPH20 with oncolytic reovirus therapy and anti-programmed cell death protein ligand-1 (PD-L1)-targeting antibody (anti-PD-L1) resulted in enhanced anti-tumour activity and also extended survival.